View ValuationFDC 将来の成長Future 基準チェック /06現在、 FDCの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長16.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報Price Target Changed • Nov 16Price target increased to ₹375Up from ₹350, the current price target is provided by 1 analyst. New target price is 32% above last closing price of ₹285. Stock is down 3.4% over the past year. The company is forecast to post earnings per share of ₹20.60 for next year compared to ₹12.82 last year.Price Target Changed • Apr 27Price target decreased to ₹415Down from ₹460, the current price target is provided by 1 analyst. New target price is 52% above last closing price of ₹273. Stock is down 12% over the past year. The company is forecast to post earnings per share of ₹17.60 for next year compared to ₹17.73 last year.Price Target Changed • Nov 16Price target decreased to ₹415Down from ₹470, the current price target is provided by 1 analyst. New target price is 40% above last closing price of ₹297. Stock is down 8.8% over the past year. The company is forecast to post earnings per share of ₹20.80 for next year compared to ₹17.73 last year.Price Target Changed • Feb 10Price target raised to ₹470Up from ₹425, the current price target is an average from 2 analysts. The new target price is 69% above the current share price of ₹279. As of last close, the stock is up 11% over the past year.すべての更新を表示Recent updatesReported Earnings • Feb 07Third quarter 2026 earnings released: EPS: ₹1.74 (vs ₹2.28 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.74 (down from ₹2.28 in 3Q 2025). Revenue: ₹4.86b (up 4.6% from 3Q 2025). Net income: ₹283.0m (down 24% from 3Q 2025). Profit margin: 5.8% (down from 8.0% in 3Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 12% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Nov 06Second quarter 2026 earnings releasedSecond quarter 2026 results: Revenue: ₹4.94b (down 3.9% from 2Q 2025). Net income: ₹283.7m (down 61% from 2Q 2025). Profit margin: 5.7% (down from 14% in 2Q 2025). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.お知らせ • Oct 20+ 1 more updateFDC Limited Announces CFO ChangesFDC Limited informed Mr. Vijay Dharmadatt Bhatt has resigned from the position of Chief Financial Officer (CFO) of the Company in order to pursue better prospects. The Board of Directors, at its meeting held on October 17, 2025, noted and accepted his resignation. Mr. Vijay D. Bhatt will be relieved from the responsibility of CFO after the close of business hours on October 20, 2025. The company further informed that based on the recommendation of the Nomination and Remuneration Committee and the Audit Committee, the Board of Directors of the Company have at its meeting held on October 17, 2025, approved the appointment of Mr. Vishal Shah as the Chief Financial Officer with effect from 24th October, 2025. Mr. Vishal Shah has about 20 years of work experience with an established track record of handling diverse finance portfolios like Business Finance, Costing, Financial Reporting and Treasury in the pharmaceutical industry.お知らせ • Aug 29+ 2 more updatesFDC Limited to Report Q2, 2026 Results on Nov 05, 2025FDC Limited announced that they will report Q2, 2026 results on Nov 05, 2025お知らせ • Aug 26FDC Limited, Annual General Meeting, Sep 25, 2025FDC Limited, Annual General Meeting, Sep 25, 2025, at 10:00 Indian Standard Time.New Risk • Aug 08New major risk - Revenue and earnings growthEarnings have declined by 0.3% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.3% per year over the past 5 years. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.Reported Earnings • Aug 08First quarter 2026 earnings released: EPS: ₹7.45 (vs ₹7.31 in 1Q 2025)First quarter 2026 results: EPS: ₹7.45 (up from ₹7.31 in 1Q 2025). Revenue: ₹6.84b (up 7.2% from 1Q 2025). Net income: ₹1.21b (up 1.9% from 1Q 2025). Profit margin: 18% (in line with 1Q 2025). Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 22% per year.お知らせ • Aug 02FDC Limited to Report Q1, 2026 Results on Aug 07, 2025FDC Limited announced that they will report Q1, 2026 results on Aug 07, 2025Reported Earnings • May 29Full year 2025 earnings released: EPS: ₹16.39 (vs ₹18.59 in FY 2024)Full year 2025 results: EPS: ₹16.39 (down from ₹18.59 in FY 2024). Revenue: ₹22.0b (up 13% from FY 2024). Net income: ₹2.67b (down 13% from FY 2024). Profit margin: 12% (down from 16% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 22% per year.お知らせ • May 22FDC Limited to Report Q4, 2025 Results on May 28, 2025FDC Limited announced that they will report Q4, 2025 results on May 28, 2025Reported Earnings • Feb 14Third quarter 2025 earnings released: EPS: ₹2.28 (vs ₹4.86 in 3Q 2024)Third quarter 2025 results: EPS: ₹2.28 (down from ₹4.86 in 3Q 2024). Revenue: ₹4.64b (up 1.3% from 3Q 2024). Net income: ₹370.4m (down 53% from 3Q 2024). Profit margin: 8.0% (down from 17% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.Buy Or Sell Opportunity • Feb 10Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 7.5% to ₹461. The fair value is estimated to be ₹586, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 14%.お知らせ • Feb 07FDC Limited to Report Q3, 2025 Results on Feb 12, 2025FDC Limited announced that they will report Q3, 2025 results on Feb 12, 2025Buy Or Sell Opportunity • Jan 22Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 9.7% to ₹466. The fair value is estimated to be ₹586, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 14%.お知らせ • Dec 19FDC Limited Receives Final Approval from US FDA for the Company's Abbreviated New Drug Application for Cefixime 400 mg TabletsFDC Limited announced that the Company has received final approval from US FDA for the Company's Abbreviated New Drug Application (ANDA) for Cefixime 400 mg Tablets.Upcoming Dividend • Nov 15Upcoming dividend of ₹5.00 per shareEligible shareholders must have bought the stock before 22 November 2024. Payment date: 06 December 2024. Payout ratio is a comfortable 26% and this is well supported by cash flows. Trailing yield: 2.0%. Within top quartile of Indian dividend payers (1.2%). Higher than average of industry peers (0.7%).Reported Earnings • Nov 07Second quarter 2025 earnings released: EPS: ₹4.43 (vs ₹4.22 in 2Q 2024)Second quarter 2025 results: EPS: ₹4.43 (up from ₹4.22 in 2Q 2024). Revenue: ₹5.49b (up 13% from 2Q 2024). Net income: ₹720.4m (up 3.2% from 2Q 2024). Profit margin: 13% (down from 14% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 18% per year.お知らせ • Oct 29FDC Limited to Report Q2, 2025 Results on Nov 06, 2024FDC Limited announced that they will report Q2, 2025 results on Nov 06, 2024お知らせ • Sep 06FDC Limited Announces Cessation of CA Swati Sandesh Mayekar as Non-Independent DirectorFDC Limited announced that CA. Swati Sandesh Mayekar Non-Executive Independent Director of the Company have completed her tenure viz. second term of five (5) consecutive years on September 05, 2024 Consequently, she ceases to be the Independent Director of the company, accordingly she also ceases to be the member of various Board committees with effect from 06 September 2024.お知らせ • Aug 28FDC Limited, Annual General Meeting, Sep 26, 2024FDC Limited, Annual General Meeting, Sep 26, 2024, at 10:00 Indian Standard Time.Reported Earnings • Aug 08First quarter 2025 earnings released: EPS: ₹7.31 (vs ₹6.62 in 1Q 2024)First quarter 2025 results: EPS: ₹7.31 (up from ₹6.62 in 1Q 2024). Revenue: ₹6.67b (up 24% from 1Q 2024). Net income: ₹1.19b (up 8.3% from 1Q 2024). Profit margin: 18% (down from 21% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 11% per year.お知らせ • Jul 26FDC Limited to Report Q1, 2025 Results on Aug 07, 2024FDC Limited announced that they will report Q1, 2025 results on Aug 07, 2024Reported Earnings • May 30Full year 2024 earnings released: EPS: ₹18.58 (vs ₹11.67 in FY 2023)Full year 2024 results: EPS: ₹18.58 (up from ₹11.67 in FY 2023). Revenue: ₹20.4b (up 15% from FY 2023). Net income: ₹3.05b (up 57% from FY 2023). Profit margin: 15% (up from 11% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.お知らせ • May 03FDC Limited Announces Board Completion of Tenure of Independent DirectorsFDC Limited announced that took note of the Completion of tenure of Independent Directors of the Company, namely, Ms. Usha Athreya Chandrasekhar and Mr. Melarkode Ganesan Parameswaran on May 9, 2024.Reported Earnings • Feb 08Third quarter 2024 earnings released: EPS: ₹4.86 (vs ₹2.45 in 3Q 2023)Third quarter 2024 results: EPS: ₹4.86 (up from ₹2.45 in 3Q 2023). Revenue: ₹4.83b (up 18% from 3Q 2023). Net income: ₹792.3m (up 95% from 3Q 2023). Profit margin: 16% (up from 10.0% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings.Reported Earnings • Nov 09Second quarter 2024 earnings released: EPS: ₹4.22 (vs ₹3.10 in 2Q 2023)Second quarter 2024 results: EPS: ₹4.22 (up from ₹3.10 in 2Q 2023). Revenue: ₹5.14b (up 15% from 2Q 2023). Net income: ₹698.2m (up 35% from 2Q 2023). Profit margin: 14% (up from 12% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.お知らせ • Sep 05+ 2 more updatesFDC Limited to Report Fiscal Year 2024 Results on May 29, 2024FDC Limited announced that they will report fiscal year 2024 results on May 29, 2024お知らせ • Aug 31FDC Limited, Annual General Meeting, Sep 27, 2023FDC Limited, Annual General Meeting, Sep 27, 2023, at 10:00 Indian Standard Time.お知らせ • Aug 10+ 1 more updateFDC Limited (BSE:531599) agreed to acquire remaining 7% stake in Fair Deal Corporation Pharmaceutical SA (Pty) Ltd. from other existing shareholders.FDC Limited (BSE:531599) agreed to acquire remaining 7% stake in Fair Deal Corporation Pharmaceutical SA (Pty) Ltd. from other existing shareholders on July 13, 2023. The consideration for this transaction will be paid in cash with settlement of their existing outstanding loan with interest. Post completion of this transaction Fair Deal Corporation Pharmaceutical SA (Pty) Ltd will become the wholly owned subsidiary of FDC Limited. Fair Deal Corporation Pharmaceutical SA (Pty) Ltd generated the revenue of ZAR 11.9 million for the year ended March 31, 2023. The transaction has been approved by the Audit Committee and Board of Directors of FDC Limited. The deal is subject to necessary approvals and regulatory compliances.New Risk • Aug 10New major risk - Revenue and earnings growthEarnings have declined by 1.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.Reported Earnings • Aug 10First quarter 2024 earnings released: EPS: ₹6.62 (vs ₹4.23 in 1Q 2023)First quarter 2024 results: EPS: ₹6.62 (up from ₹4.23 in 1Q 2023). Revenue: ₹5.66b (up 14% from 1Q 2023). Net income: ₹1.10b (up 55% from 1Q 2023). Profit margin: 19% (up from 14% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.お知らせ • Aug 03FDC Limited to Report Q1, 2024 Results on Aug 09, 2023FDC Limited announced that they will report Q1, 2024 results on Aug 09, 2023Reported Earnings • May 30Full year 2023 earnings released: EPS: ₹11.66 (vs ₹12.82 in FY 2022)Full year 2023 results: EPS: ₹11.66 (down from ₹12.82 in FY 2022). Revenue: ₹18.3b (up 20% from FY 2022). Net income: ₹1.94b (down 10% from FY 2022). Profit margin: 11% (down from 14% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.Reported Earnings • May 30Full year 2023 earnings released: EPS: ₹11.66 (vs ₹12.82 in FY 2022)Full year 2023 results: EPS: ₹11.66 (down from ₹12.82 in FY 2022). Revenue: ₹18.3b (up 20% from FY 2022). Net income: ₹1.94b (down 10% from FY 2022). Profit margin: 11% (down from 14% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.Reported Earnings • Feb 10Third quarter 2023 earnings released: EPS: ₹2.45 (vs ₹2.11 in 3Q 2022)Third quarter 2023 results: EPS: ₹2.45 (up from ₹2.11 in 3Q 2022). Revenue: ₹4.28b (up 25% from 3Q 2022). Net income: ₹407.5m (up 14% from 3Q 2022). Profit margin: 9.5% (in line with 3Q 2022). Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.お知らせ • Feb 01FDC Limited to Report Q3, 2023 Results on Feb 09, 2023FDC Limited announced that they will report Q3, 2023 results on Feb 09, 2023Reported Earnings • Nov 18Second quarter 2023 earnings released: EPS: ₹3.10 (vs ₹4.28 in 2Q 2022)Second quarter 2023 results: EPS: ₹3.10 (down from ₹4.28 in 2Q 2022). Revenue: ₹4.45b (up 12% from 2Q 2022). Net income: ₹518.4m (down 28% from 2Q 2022). Profit margin: 12% (down from 18% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.Price Target Changed • Nov 16Price target increased to ₹375Up from ₹350, the current price target is provided by 1 analyst. New target price is 32% above last closing price of ₹285. Stock is down 3.4% over the past year. The company is forecast to post earnings per share of ₹20.60 for next year compared to ₹12.82 last year.お知らせ • Sep 23FDC Limited Approves Appointment of Vijay S. Maniar as an Non-Executive and Independent DirectorFDC Limited announced that the appointment of Mr. Vijay S. Maniar as an non-executive and independent director of the company, with effect from August 4, 2022 till August 3, 2027 has been approved by the shareholders at the 82 Annual General Meeting (`AGM') of the company, held on September 22, 2022, through video conferencing. Education: A Fellow member of the Institute of Chartered Accountants of India (ICAI) having over 35 years of professional experience. Work Experience: ASA & Associates (Top 10 Accounting and Consulting Firm of India) January 2022 – Present: Advisor and Mentor to guide the Mumbai branch operations and teams, including the leadership team to strengthen the practice. S R Batliboi & Co LLP (Indian member firm of EY Global) 1999 – 2021: Engagement partner for statutory audits of large listed as well as unlisted corporates (Indian /multinational /entrepreneurial /PE funded) including those which undertook capital market transactions; Listed corporates include Grasim Industries, Avenue Supermart (DMart), Aditya Birla Fashion and Retail, Shoppers Stop, Huhtamaki Paper Products, Aditya Birla Nuvo, Sanofi, FDC, Excel Industries, Excel Crop Care (now Sumitomo Chemicals), lon Exchange; Sector focused - Retail, Pharma and Chemicals, Packaging, Hospitality, Manufacturing and Real Estate; Extensive audit committee/board meeting experience having attended more than 400 meetings; Special Invitee on Accounting Standards Board (ASB) of ICAI for 2 years; Member of Accounting and Auditing Committee of Bombay Chartered Accountants Society (BCAS) since more than 15 years; Regular speaker at various forums; Co-author of: Guidance Notes on Division |, Il and Ill of Revised Schedule Ill to the Companies Act 2013 issued by ICAI; Guidance Note on Revised Schedule VI to the Companies Act, 1956 issued by ICAI and Mandatory Accounting Standards -- Extracts from Published Accounts issued by BCAS. Maniar & Maniar /Chandrakant Mehta & Associates 1985 – 1999: Set up professional practice and created infrastructure; Engaged with entrepreneurs as a trusted advisor and sounding board; Developed and mentored team to grow with me.お知らせ • Aug 30+ 2 more updatesFDC Limited to Report Q4, 2023 Results on May 23, 2023FDC Limited announced that they will report Q4, 2023 results on May 23, 2023Reported Earnings • Aug 05First quarter 2023 earnings released: EPS: ₹4.23 (vs ₹5.80 in 1Q 2022)First quarter 2023 results: EPS: ₹4.23 (down from ₹5.80 in 1Q 2022). Revenue: ₹5.14b (up 15% from 1Q 2022). Net income: ₹707.4m (down 28% from 1Q 2022). Profit margin: 14% (down from 22% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jul 22FDC Limited to Report Q1, 2023 Results on Aug 04, 2022FDC Limited announced that they will report Q1, 2023 results on Aug 04, 2022Recent Insider Transactions • Jun 11Board Member recently bought ₹912k worth of stockOn the 8th of June, Melarkode Parameswaran bought around 4k shares on-market at roughly ₹247 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Board Change • Jun 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 3 highly experienced directors. Additional Non-Executive & Independent Director Ambi Parameswaran was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • May 27Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: EPS: ₹12.81 (down from ₹17.73 in FY 2021). Net income: ₹2.16b (down 28% from FY 2021). Revenue missed analyst estimates by 3.1%. Earnings per share (EPS) also missed analyst estimates by 27%. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.お知らせ • May 15FDC Limited to Report Q4, 2022 Results on May 25, 2022FDC Limited announced that they will report Q4, 2022 results on May 25, 2022Price Target Changed • Apr 27Price target decreased to ₹415Down from ₹460, the current price target is provided by 1 analyst. New target price is 52% above last closing price of ₹273. Stock is down 12% over the past year. The company is forecast to post earnings per share of ₹17.60 for next year compared to ₹17.73 last year.お知らせ • Apr 01Fdc Limited Announces That Nomita R. Chandavarkar Has Stepped Down from the Position of the Executive Director of the Company to Non-Executive Director with Effect from April 01, 2022FDC Limited announced that Ms. Nomita R. Chandavarkar has stepped down from the position of the Executive Director of the Company to Non-Executive Director with effect from April 01, 2022. Therefore she continues to be on the Board of the Company as Non-Executive Non-Independent Director.Reported Earnings • Feb 10Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: EPS: ₹2.11 (down from ₹4.45 in 3Q 2021). Revenue: ₹3.55b (up 4.2% from 3Q 2021). Net income: ₹356.9m (down 53% from 3Q 2021). Profit margin: 10% (down from 22% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 9.5%. Earnings per share (EPS) also missed analyst estimates by 7.7%. Over the next year, revenue is forecast to grow 22%, compared to a 13% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 25% per year.お知らせ • Feb 10FDC Limited (BSE:531599) announces an Equity Buyback for 2,900,000 shares, representing 1.72% for INR 1,377.5 million.FDC Limited (BSE:531599) announces a share repurchase program. Under the program, the company will repurchase up to 2,900,000 shares, representing 1.72% of its issued share capital for INR 1,377.5 million. The shares will be repurchased at a price of INR 475 per share. The company has fixed February 19, 2022, as the record date. As of February 9, 2022, the company had 168,810,084 shares in issue.Reported Earnings • Nov 16Second quarter 2022 earnings released: EPS ₹4.28 (vs ₹5.15 in 2Q 2021)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: ₹3.98b (up 7.1% from 2Q 2021). Net income: ₹724.0m (down 18% from 2Q 2021). Profit margin: 18% (down from 24% in 2Q 2021). The decrease in margin was driven by higher expenses.Price Target Changed • Nov 16Price target decreased to ₹415Down from ₹470, the current price target is provided by 1 analyst. New target price is 40% above last closing price of ₹297. Stock is down 8.8% over the past year. The company is forecast to post earnings per share of ₹20.80 for next year compared to ₹17.73 last year.Reported Earnings • Aug 18First quarter 2022 earnings released: EPS ₹5.80 (vs ₹5.36 in 1Q 2021)The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2022 results: Revenue: ₹4.47b (up 45% from 1Q 2021). Net income: ₹978.7m (up 6.7% from 1Q 2021). Profit margin: 22% (down from 30% in 1Q 2021). The decrease in margin was driven by higher expenses.お知らせ • Jul 14FDC Limited Launches Favipiravir Oral Suspension -FavenzaFDC Limited announced the launch of India's first oral suspension of Favipiravir - Favenza Oral Suspension, used to treat mild to moderate cases of COVID-19. This prescription-only solution is currently available at all retail medical outlets and hospita pharmacies across the country. The Favenza suspension is unique due to its Convenient Loading Dose (Day 1) of 18 ml in the morning and 18 ml in the evening. The results of which are equivalent to 9 tablets of Favipiravir 400mg making the process of Covid-19 treatment hassle free.Reported Earnings • May 28Full year 2021 earnings released: EPS ₹17.72 (vs ₹13.94 in FY 2020)The company reported a decent full year result with improved earnings and profit margins, although revenues were flat. Full year 2021 results: Revenue: ₹13.3b (flat on FY 2020). Net income: ₹3.01b (up 26% from FY 2020). Profit margin: 23% (up from 18% in FY 2020). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.Price Target Changed • Feb 10Price target raised to ₹470Up from ₹425, the current price target is an average from 2 analysts. The new target price is 69% above the current share price of ₹279. As of last close, the stock is up 11% over the past year.Is New 90 Day High Low • Feb 08New 90-day low: ₹280The company is down 13% from its price of ₹322 on 10 November 2020. The Indian market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₹156 per share.Reported Earnings • Feb 05Third quarter 2021 earnings released: EPS ₹4.47 (vs ₹4.31 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: ₹3.75b (up 17% from 3Q 2020). Net income: ₹752.5m (up 1.5% from 3Q 2020). Profit margin: 20% (down from 23% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.お知らせ • Jan 28FDC Limited to Report Q3, 2021 Results on Feb 04, 2021FDC Limited announced that they will report Q3, 2021 results on Feb 04, 2021Is New 90 Day High Low • Jan 21New 90-day low: ₹311The company is down 10.0% from its price of ₹347 on 23 October 2020. The Indian market is up 24% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₹92.93 per share.Reported Earnings • Nov 10Second quarter 2021 earnings released: EPS ₹5.15The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₹3.90b (up 13% from 2Q 2020). Net income: ₹880.8m (up 63% from 2Q 2020). Profit margin: 23% (up from 16% in 2Q 2020). The increase in margin was driven by higher revenue.Analyst Estimate Surprise Post Earnings • Nov 10Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 14%. Earnings per share (EPS) also surpassed analyst estimates by 22%. Over the next year, revenue is forecast to grow 16%, compared to a 12% growth forecast for the Pharmaceuticals industry in India.Is New 90 Day High Low • Oct 07New 90-day high: ₹368The company is up 50% from its price of ₹245 on 09 July 2020. The Indian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 20% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₹273 per share.お知らせ • Sep 12FDC Limited to Report Q1, 2021 Results on Aug 07, 2020FDC Limited announced that they will report Q1, 2021 results on Aug 07, 2020お知らせ • Aug 08FDC Limited (BSE:531599) entered into definitive agreements to acquire an additional 44% stake in Fair Deal Corporation Pharmaceutical SA (Pty) Ltd from Pharma-Q Holdings Pty for ZAR 0.14 million.FDC Limited (BSE:531599) entered into definitive agreements to acquire an additional 44% stake in Fair Deal Corporation Pharmaceutical SA (Pty) Ltd from Pharma-Q Holdings Pty for ZAR 0.14 million on August 7, 2020. The consideration will be paid in cash for 0.143 million shares. Post acquisition Fair Deal Corporation Pharmaceutical will became a subsidiary of FDC, owning 93% stake. The transaction also involves settlement of outstanding loan of ZAR 6.5 million equivalent to availed by Fair Deal Corporation Pharmaceutical from Pharma Q. For the year ended March 31, 2020, Fair Deal Corporation Pharmaceutical reported revenue of ZAR 2.97 million and loss after tax of ZAR 4.3 million. The said transaction is subject to completion of various closing conditions. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、FDC は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測BSE:531599 - アナリストの将来予測と過去の財務データ ( )INR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202520,7802,167N/AN/AN/A9/30/202520,7742,254-561912N/A6/30/202521,1832,691N/AN/AN/A3/31/202521,0812,6682,2083,176N/A12/31/202420,7832,744N/AN/AN/A9/30/202420,7233,1662,5263,202N/A6/30/202420,4483,144N/AN/AN/A3/31/202419,4293,0521,2742,208N/A12/31/202319,1572,897N/AN/AN/A9/30/202318,6682,5121,0302,143N/A6/30/202318,2552,332N/AN/AN/A3/31/202317,8381,9404181,549N/A12/31/202216,9001,738N/AN/AN/A9/30/202216,2251,687-1,006655N/A6/30/202215,7511,893N/AN/AN/A3/31/202215,2792,1642911,617N/A12/31/202115,0032,522N/AN/AN/A9/30/202114,9872,9181,6702,422N/A6/30/202114,7253,075N/AN/AN/A3/31/202113,3323,0131,4452,071N/A12/31/202013,5313,106N/AN/AN/A9/30/202013,3413,0941,9802,267N/A6/30/202013,0892,754N/AN/AN/A3/31/202013,4422,3992,1912,504N/A12/31/201912,8152,192N/AN/AN/A9/30/201912,1651,909N/A1,738N/A6/30/201911,4421,771N/AN/AN/A3/31/201910,9071,698N/A1,124N/A3/31/201810,7511,735N/A1,498N/A3/31/201710,1391,885N/A1,545N/A3/31/20169,9431,687N/A1,743N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 531599の予測収益成長が 貯蓄率 ( 6.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 531599の収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 531599の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 531599の収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 531599の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 531599の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 00:56終値2026/05/22 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋FDC Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関null nullCentrum Broking LimitedKameswari V. S. ChavaliFirstCall Research
Price Target Changed • Nov 16Price target increased to ₹375Up from ₹350, the current price target is provided by 1 analyst. New target price is 32% above last closing price of ₹285. Stock is down 3.4% over the past year. The company is forecast to post earnings per share of ₹20.60 for next year compared to ₹12.82 last year.
Price Target Changed • Apr 27Price target decreased to ₹415Down from ₹460, the current price target is provided by 1 analyst. New target price is 52% above last closing price of ₹273. Stock is down 12% over the past year. The company is forecast to post earnings per share of ₹17.60 for next year compared to ₹17.73 last year.
Price Target Changed • Nov 16Price target decreased to ₹415Down from ₹470, the current price target is provided by 1 analyst. New target price is 40% above last closing price of ₹297. Stock is down 8.8% over the past year. The company is forecast to post earnings per share of ₹20.80 for next year compared to ₹17.73 last year.
Price Target Changed • Feb 10Price target raised to ₹470Up from ₹425, the current price target is an average from 2 analysts. The new target price is 69% above the current share price of ₹279. As of last close, the stock is up 11% over the past year.
Reported Earnings • Feb 07Third quarter 2026 earnings released: EPS: ₹1.74 (vs ₹2.28 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.74 (down from ₹2.28 in 3Q 2025). Revenue: ₹4.86b (up 4.6% from 3Q 2025). Net income: ₹283.0m (down 24% from 3Q 2025). Profit margin: 5.8% (down from 8.0% in 3Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 12% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Nov 06Second quarter 2026 earnings releasedSecond quarter 2026 results: Revenue: ₹4.94b (down 3.9% from 2Q 2025). Net income: ₹283.7m (down 61% from 2Q 2025). Profit margin: 5.7% (down from 14% in 2Q 2025). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.
お知らせ • Oct 20+ 1 more updateFDC Limited Announces CFO ChangesFDC Limited informed Mr. Vijay Dharmadatt Bhatt has resigned from the position of Chief Financial Officer (CFO) of the Company in order to pursue better prospects. The Board of Directors, at its meeting held on October 17, 2025, noted and accepted his resignation. Mr. Vijay D. Bhatt will be relieved from the responsibility of CFO after the close of business hours on October 20, 2025. The company further informed that based on the recommendation of the Nomination and Remuneration Committee and the Audit Committee, the Board of Directors of the Company have at its meeting held on October 17, 2025, approved the appointment of Mr. Vishal Shah as the Chief Financial Officer with effect from 24th October, 2025. Mr. Vishal Shah has about 20 years of work experience with an established track record of handling diverse finance portfolios like Business Finance, Costing, Financial Reporting and Treasury in the pharmaceutical industry.
お知らせ • Aug 29+ 2 more updatesFDC Limited to Report Q2, 2026 Results on Nov 05, 2025FDC Limited announced that they will report Q2, 2026 results on Nov 05, 2025
お知らせ • Aug 26FDC Limited, Annual General Meeting, Sep 25, 2025FDC Limited, Annual General Meeting, Sep 25, 2025, at 10:00 Indian Standard Time.
New Risk • Aug 08New major risk - Revenue and earnings growthEarnings have declined by 0.3% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.3% per year over the past 5 years. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
Reported Earnings • Aug 08First quarter 2026 earnings released: EPS: ₹7.45 (vs ₹7.31 in 1Q 2025)First quarter 2026 results: EPS: ₹7.45 (up from ₹7.31 in 1Q 2025). Revenue: ₹6.84b (up 7.2% from 1Q 2025). Net income: ₹1.21b (up 1.9% from 1Q 2025). Profit margin: 18% (in line with 1Q 2025). Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 22% per year.
お知らせ • Aug 02FDC Limited to Report Q1, 2026 Results on Aug 07, 2025FDC Limited announced that they will report Q1, 2026 results on Aug 07, 2025
Reported Earnings • May 29Full year 2025 earnings released: EPS: ₹16.39 (vs ₹18.59 in FY 2024)Full year 2025 results: EPS: ₹16.39 (down from ₹18.59 in FY 2024). Revenue: ₹22.0b (up 13% from FY 2024). Net income: ₹2.67b (down 13% from FY 2024). Profit margin: 12% (down from 16% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 22% per year.
お知らせ • May 22FDC Limited to Report Q4, 2025 Results on May 28, 2025FDC Limited announced that they will report Q4, 2025 results on May 28, 2025
Reported Earnings • Feb 14Third quarter 2025 earnings released: EPS: ₹2.28 (vs ₹4.86 in 3Q 2024)Third quarter 2025 results: EPS: ₹2.28 (down from ₹4.86 in 3Q 2024). Revenue: ₹4.64b (up 1.3% from 3Q 2024). Net income: ₹370.4m (down 53% from 3Q 2024). Profit margin: 8.0% (down from 17% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.
Buy Or Sell Opportunity • Feb 10Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 7.5% to ₹461. The fair value is estimated to be ₹586, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 14%.
お知らせ • Feb 07FDC Limited to Report Q3, 2025 Results on Feb 12, 2025FDC Limited announced that they will report Q3, 2025 results on Feb 12, 2025
Buy Or Sell Opportunity • Jan 22Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 9.7% to ₹466. The fair value is estimated to be ₹586, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 14%.
お知らせ • Dec 19FDC Limited Receives Final Approval from US FDA for the Company's Abbreviated New Drug Application for Cefixime 400 mg TabletsFDC Limited announced that the Company has received final approval from US FDA for the Company's Abbreviated New Drug Application (ANDA) for Cefixime 400 mg Tablets.
Upcoming Dividend • Nov 15Upcoming dividend of ₹5.00 per shareEligible shareholders must have bought the stock before 22 November 2024. Payment date: 06 December 2024. Payout ratio is a comfortable 26% and this is well supported by cash flows. Trailing yield: 2.0%. Within top quartile of Indian dividend payers (1.2%). Higher than average of industry peers (0.7%).
Reported Earnings • Nov 07Second quarter 2025 earnings released: EPS: ₹4.43 (vs ₹4.22 in 2Q 2024)Second quarter 2025 results: EPS: ₹4.43 (up from ₹4.22 in 2Q 2024). Revenue: ₹5.49b (up 13% from 2Q 2024). Net income: ₹720.4m (up 3.2% from 2Q 2024). Profit margin: 13% (down from 14% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 18% per year.
お知らせ • Oct 29FDC Limited to Report Q2, 2025 Results on Nov 06, 2024FDC Limited announced that they will report Q2, 2025 results on Nov 06, 2024
お知らせ • Sep 06FDC Limited Announces Cessation of CA Swati Sandesh Mayekar as Non-Independent DirectorFDC Limited announced that CA. Swati Sandesh Mayekar Non-Executive Independent Director of the Company have completed her tenure viz. second term of five (5) consecutive years on September 05, 2024 Consequently, she ceases to be the Independent Director of the company, accordingly she also ceases to be the member of various Board committees with effect from 06 September 2024.
お知らせ • Aug 28FDC Limited, Annual General Meeting, Sep 26, 2024FDC Limited, Annual General Meeting, Sep 26, 2024, at 10:00 Indian Standard Time.
Reported Earnings • Aug 08First quarter 2025 earnings released: EPS: ₹7.31 (vs ₹6.62 in 1Q 2024)First quarter 2025 results: EPS: ₹7.31 (up from ₹6.62 in 1Q 2024). Revenue: ₹6.67b (up 24% from 1Q 2024). Net income: ₹1.19b (up 8.3% from 1Q 2024). Profit margin: 18% (down from 21% in 1Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 11% per year.
お知らせ • Jul 26FDC Limited to Report Q1, 2025 Results on Aug 07, 2024FDC Limited announced that they will report Q1, 2025 results on Aug 07, 2024
Reported Earnings • May 30Full year 2024 earnings released: EPS: ₹18.58 (vs ₹11.67 in FY 2023)Full year 2024 results: EPS: ₹18.58 (up from ₹11.67 in FY 2023). Revenue: ₹20.4b (up 15% from FY 2023). Net income: ₹3.05b (up 57% from FY 2023). Profit margin: 15% (up from 11% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.
お知らせ • May 03FDC Limited Announces Board Completion of Tenure of Independent DirectorsFDC Limited announced that took note of the Completion of tenure of Independent Directors of the Company, namely, Ms. Usha Athreya Chandrasekhar and Mr. Melarkode Ganesan Parameswaran on May 9, 2024.
Reported Earnings • Feb 08Third quarter 2024 earnings released: EPS: ₹4.86 (vs ₹2.45 in 3Q 2023)Third quarter 2024 results: EPS: ₹4.86 (up from ₹2.45 in 3Q 2023). Revenue: ₹4.83b (up 18% from 3Q 2023). Net income: ₹792.3m (up 95% from 3Q 2023). Profit margin: 16% (up from 10.0% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings.
Reported Earnings • Nov 09Second quarter 2024 earnings released: EPS: ₹4.22 (vs ₹3.10 in 2Q 2023)Second quarter 2024 results: EPS: ₹4.22 (up from ₹3.10 in 2Q 2023). Revenue: ₹5.14b (up 15% from 2Q 2023). Net income: ₹698.2m (up 35% from 2Q 2023). Profit margin: 14% (up from 12% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.
お知らせ • Sep 05+ 2 more updatesFDC Limited to Report Fiscal Year 2024 Results on May 29, 2024FDC Limited announced that they will report fiscal year 2024 results on May 29, 2024
お知らせ • Aug 31FDC Limited, Annual General Meeting, Sep 27, 2023FDC Limited, Annual General Meeting, Sep 27, 2023, at 10:00 Indian Standard Time.
お知らせ • Aug 10+ 1 more updateFDC Limited (BSE:531599) agreed to acquire remaining 7% stake in Fair Deal Corporation Pharmaceutical SA (Pty) Ltd. from other existing shareholders.FDC Limited (BSE:531599) agreed to acquire remaining 7% stake in Fair Deal Corporation Pharmaceutical SA (Pty) Ltd. from other existing shareholders on July 13, 2023. The consideration for this transaction will be paid in cash with settlement of their existing outstanding loan with interest. Post completion of this transaction Fair Deal Corporation Pharmaceutical SA (Pty) Ltd will become the wholly owned subsidiary of FDC Limited. Fair Deal Corporation Pharmaceutical SA (Pty) Ltd generated the revenue of ZAR 11.9 million for the year ended March 31, 2023. The transaction has been approved by the Audit Committee and Board of Directors of FDC Limited. The deal is subject to necessary approvals and regulatory compliances.
New Risk • Aug 10New major risk - Revenue and earnings growthEarnings have declined by 1.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
Reported Earnings • Aug 10First quarter 2024 earnings released: EPS: ₹6.62 (vs ₹4.23 in 1Q 2023)First quarter 2024 results: EPS: ₹6.62 (up from ₹4.23 in 1Q 2023). Revenue: ₹5.66b (up 14% from 1Q 2023). Net income: ₹1.10b (up 55% from 1Q 2023). Profit margin: 19% (up from 14% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.
お知らせ • Aug 03FDC Limited to Report Q1, 2024 Results on Aug 09, 2023FDC Limited announced that they will report Q1, 2024 results on Aug 09, 2023
Reported Earnings • May 30Full year 2023 earnings released: EPS: ₹11.66 (vs ₹12.82 in FY 2022)Full year 2023 results: EPS: ₹11.66 (down from ₹12.82 in FY 2022). Revenue: ₹18.3b (up 20% from FY 2022). Net income: ₹1.94b (down 10% from FY 2022). Profit margin: 11% (down from 14% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.
Reported Earnings • May 30Full year 2023 earnings released: EPS: ₹11.66 (vs ₹12.82 in FY 2022)Full year 2023 results: EPS: ₹11.66 (down from ₹12.82 in FY 2022). Revenue: ₹18.3b (up 20% from FY 2022). Net income: ₹1.94b (down 10% from FY 2022). Profit margin: 11% (down from 14% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.
Reported Earnings • Feb 10Third quarter 2023 earnings released: EPS: ₹2.45 (vs ₹2.11 in 3Q 2022)Third quarter 2023 results: EPS: ₹2.45 (up from ₹2.11 in 3Q 2022). Revenue: ₹4.28b (up 25% from 3Q 2022). Net income: ₹407.5m (up 14% from 3Q 2022). Profit margin: 9.5% (in line with 3Q 2022). Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
お知らせ • Feb 01FDC Limited to Report Q3, 2023 Results on Feb 09, 2023FDC Limited announced that they will report Q3, 2023 results on Feb 09, 2023
Reported Earnings • Nov 18Second quarter 2023 earnings released: EPS: ₹3.10 (vs ₹4.28 in 2Q 2022)Second quarter 2023 results: EPS: ₹3.10 (down from ₹4.28 in 2Q 2022). Revenue: ₹4.45b (up 12% from 2Q 2022). Net income: ₹518.4m (down 28% from 2Q 2022). Profit margin: 12% (down from 18% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.
Price Target Changed • Nov 16Price target increased to ₹375Up from ₹350, the current price target is provided by 1 analyst. New target price is 32% above last closing price of ₹285. Stock is down 3.4% over the past year. The company is forecast to post earnings per share of ₹20.60 for next year compared to ₹12.82 last year.
お知らせ • Sep 23FDC Limited Approves Appointment of Vijay S. Maniar as an Non-Executive and Independent DirectorFDC Limited announced that the appointment of Mr. Vijay S. Maniar as an non-executive and independent director of the company, with effect from August 4, 2022 till August 3, 2027 has been approved by the shareholders at the 82 Annual General Meeting (`AGM') of the company, held on September 22, 2022, through video conferencing. Education: A Fellow member of the Institute of Chartered Accountants of India (ICAI) having over 35 years of professional experience. Work Experience: ASA & Associates (Top 10 Accounting and Consulting Firm of India) January 2022 – Present: Advisor and Mentor to guide the Mumbai branch operations and teams, including the leadership team to strengthen the practice. S R Batliboi & Co LLP (Indian member firm of EY Global) 1999 – 2021: Engagement partner for statutory audits of large listed as well as unlisted corporates (Indian /multinational /entrepreneurial /PE funded) including those which undertook capital market transactions; Listed corporates include Grasim Industries, Avenue Supermart (DMart), Aditya Birla Fashion and Retail, Shoppers Stop, Huhtamaki Paper Products, Aditya Birla Nuvo, Sanofi, FDC, Excel Industries, Excel Crop Care (now Sumitomo Chemicals), lon Exchange; Sector focused - Retail, Pharma and Chemicals, Packaging, Hospitality, Manufacturing and Real Estate; Extensive audit committee/board meeting experience having attended more than 400 meetings; Special Invitee on Accounting Standards Board (ASB) of ICAI for 2 years; Member of Accounting and Auditing Committee of Bombay Chartered Accountants Society (BCAS) since more than 15 years; Regular speaker at various forums; Co-author of: Guidance Notes on Division |, Il and Ill of Revised Schedule Ill to the Companies Act 2013 issued by ICAI; Guidance Note on Revised Schedule VI to the Companies Act, 1956 issued by ICAI and Mandatory Accounting Standards -- Extracts from Published Accounts issued by BCAS. Maniar & Maniar /Chandrakant Mehta & Associates 1985 – 1999: Set up professional practice and created infrastructure; Engaged with entrepreneurs as a trusted advisor and sounding board; Developed and mentored team to grow with me.
お知らせ • Aug 30+ 2 more updatesFDC Limited to Report Q4, 2023 Results on May 23, 2023FDC Limited announced that they will report Q4, 2023 results on May 23, 2023
Reported Earnings • Aug 05First quarter 2023 earnings released: EPS: ₹4.23 (vs ₹5.80 in 1Q 2022)First quarter 2023 results: EPS: ₹4.23 (down from ₹5.80 in 1Q 2022). Revenue: ₹5.14b (up 15% from 1Q 2022). Net income: ₹707.4m (down 28% from 1Q 2022). Profit margin: 14% (down from 22% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jul 22FDC Limited to Report Q1, 2023 Results on Aug 04, 2022FDC Limited announced that they will report Q1, 2023 results on Aug 04, 2022
Recent Insider Transactions • Jun 11Board Member recently bought ₹912k worth of stockOn the 8th of June, Melarkode Parameswaran bought around 4k shares on-market at roughly ₹247 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Board Change • Jun 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 3 highly experienced directors. Additional Non-Executive & Independent Director Ambi Parameswaran was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • May 27Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: EPS: ₹12.81 (down from ₹17.73 in FY 2021). Net income: ₹2.16b (down 28% from FY 2021). Revenue missed analyst estimates by 3.1%. Earnings per share (EPS) also missed analyst estimates by 27%. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
お知らせ • May 15FDC Limited to Report Q4, 2022 Results on May 25, 2022FDC Limited announced that they will report Q4, 2022 results on May 25, 2022
Price Target Changed • Apr 27Price target decreased to ₹415Down from ₹460, the current price target is provided by 1 analyst. New target price is 52% above last closing price of ₹273. Stock is down 12% over the past year. The company is forecast to post earnings per share of ₹17.60 for next year compared to ₹17.73 last year.
お知らせ • Apr 01Fdc Limited Announces That Nomita R. Chandavarkar Has Stepped Down from the Position of the Executive Director of the Company to Non-Executive Director with Effect from April 01, 2022FDC Limited announced that Ms. Nomita R. Chandavarkar has stepped down from the position of the Executive Director of the Company to Non-Executive Director with effect from April 01, 2022. Therefore she continues to be on the Board of the Company as Non-Executive Non-Independent Director.
Reported Earnings • Feb 10Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: EPS: ₹2.11 (down from ₹4.45 in 3Q 2021). Revenue: ₹3.55b (up 4.2% from 3Q 2021). Net income: ₹356.9m (down 53% from 3Q 2021). Profit margin: 10% (down from 22% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 9.5%. Earnings per share (EPS) also missed analyst estimates by 7.7%. Over the next year, revenue is forecast to grow 22%, compared to a 13% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 25% per year.
お知らせ • Feb 10FDC Limited (BSE:531599) announces an Equity Buyback for 2,900,000 shares, representing 1.72% for INR 1,377.5 million.FDC Limited (BSE:531599) announces a share repurchase program. Under the program, the company will repurchase up to 2,900,000 shares, representing 1.72% of its issued share capital for INR 1,377.5 million. The shares will be repurchased at a price of INR 475 per share. The company has fixed February 19, 2022, as the record date. As of February 9, 2022, the company had 168,810,084 shares in issue.
Reported Earnings • Nov 16Second quarter 2022 earnings released: EPS ₹4.28 (vs ₹5.15 in 2Q 2021)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: ₹3.98b (up 7.1% from 2Q 2021). Net income: ₹724.0m (down 18% from 2Q 2021). Profit margin: 18% (down from 24% in 2Q 2021). The decrease in margin was driven by higher expenses.
Price Target Changed • Nov 16Price target decreased to ₹415Down from ₹470, the current price target is provided by 1 analyst. New target price is 40% above last closing price of ₹297. Stock is down 8.8% over the past year. The company is forecast to post earnings per share of ₹20.80 for next year compared to ₹17.73 last year.
Reported Earnings • Aug 18First quarter 2022 earnings released: EPS ₹5.80 (vs ₹5.36 in 1Q 2021)The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2022 results: Revenue: ₹4.47b (up 45% from 1Q 2021). Net income: ₹978.7m (up 6.7% from 1Q 2021). Profit margin: 22% (down from 30% in 1Q 2021). The decrease in margin was driven by higher expenses.
お知らせ • Jul 14FDC Limited Launches Favipiravir Oral Suspension -FavenzaFDC Limited announced the launch of India's first oral suspension of Favipiravir - Favenza Oral Suspension, used to treat mild to moderate cases of COVID-19. This prescription-only solution is currently available at all retail medical outlets and hospita pharmacies across the country. The Favenza suspension is unique due to its Convenient Loading Dose (Day 1) of 18 ml in the morning and 18 ml in the evening. The results of which are equivalent to 9 tablets of Favipiravir 400mg making the process of Covid-19 treatment hassle free.
Reported Earnings • May 28Full year 2021 earnings released: EPS ₹17.72 (vs ₹13.94 in FY 2020)The company reported a decent full year result with improved earnings and profit margins, although revenues were flat. Full year 2021 results: Revenue: ₹13.3b (flat on FY 2020). Net income: ₹3.01b (up 26% from FY 2020). Profit margin: 23% (up from 18% in FY 2020). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.
Price Target Changed • Feb 10Price target raised to ₹470Up from ₹425, the current price target is an average from 2 analysts. The new target price is 69% above the current share price of ₹279. As of last close, the stock is up 11% over the past year.
Is New 90 Day High Low • Feb 08New 90-day low: ₹280The company is down 13% from its price of ₹322 on 10 November 2020. The Indian market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₹156 per share.
Reported Earnings • Feb 05Third quarter 2021 earnings released: EPS ₹4.47 (vs ₹4.31 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: ₹3.75b (up 17% from 3Q 2020). Net income: ₹752.5m (up 1.5% from 3Q 2020). Profit margin: 20% (down from 23% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
お知らせ • Jan 28FDC Limited to Report Q3, 2021 Results on Feb 04, 2021FDC Limited announced that they will report Q3, 2021 results on Feb 04, 2021
Is New 90 Day High Low • Jan 21New 90-day low: ₹311The company is down 10.0% from its price of ₹347 on 23 October 2020. The Indian market is up 24% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₹92.93 per share.
Reported Earnings • Nov 10Second quarter 2021 earnings released: EPS ₹5.15The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₹3.90b (up 13% from 2Q 2020). Net income: ₹880.8m (up 63% from 2Q 2020). Profit margin: 23% (up from 16% in 2Q 2020). The increase in margin was driven by higher revenue.
Analyst Estimate Surprise Post Earnings • Nov 10Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 14%. Earnings per share (EPS) also surpassed analyst estimates by 22%. Over the next year, revenue is forecast to grow 16%, compared to a 12% growth forecast for the Pharmaceuticals industry in India.
Is New 90 Day High Low • Oct 07New 90-day high: ₹368The company is up 50% from its price of ₹245 on 09 July 2020. The Indian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 20% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₹273 per share.
お知らせ • Sep 12FDC Limited to Report Q1, 2021 Results on Aug 07, 2020FDC Limited announced that they will report Q1, 2021 results on Aug 07, 2020
お知らせ • Aug 08FDC Limited (BSE:531599) entered into definitive agreements to acquire an additional 44% stake in Fair Deal Corporation Pharmaceutical SA (Pty) Ltd from Pharma-Q Holdings Pty for ZAR 0.14 million.FDC Limited (BSE:531599) entered into definitive agreements to acquire an additional 44% stake in Fair Deal Corporation Pharmaceutical SA (Pty) Ltd from Pharma-Q Holdings Pty for ZAR 0.14 million on August 7, 2020. The consideration will be paid in cash for 0.143 million shares. Post acquisition Fair Deal Corporation Pharmaceutical will became a subsidiary of FDC, owning 93% stake. The transaction also involves settlement of outstanding loan of ZAR 6.5 million equivalent to availed by Fair Deal Corporation Pharmaceutical from Pharma Q. For the year ended March 31, 2020, Fair Deal Corporation Pharmaceutical reported revenue of ZAR 2.97 million and loss after tax of ZAR 4.3 million. The said transaction is subject to completion of various closing conditions.